The aim of the study was to investigate the impact of TP53 mutations on overall survival in a cohort of patients with refractory/relapsed DLBCL and DHL/THL, comparing patients who received CAR T-cell therapy to control patients with conventional relapse therapies. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.